Who Paid My Doc
Gilda Tafreshi
Vascular Neurology La Jolla, CA Medical Doctor
NPI 1891946950 CMS profile 85560
9898 Genesee Ave, La Jolla, CA 92037
General payments
$112
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Gilda Tafreshi of La Jolla, CA is reported in the CMS Open Payments database as having received $112 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 16th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $90 | 1 | |
| 2019 | General | $23 | 1 |
Beside peers
- Gilda Tafreshi
- Vascular Neurology median
- Middle half of Vascular Neurology
- National median
In program year 2025, general payments to Gilda Tafreshi were reported at $0. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.
Show as a table
| Year | Gilda Tafreshi | Vascular Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $23 | $263 | $102–$1,640 | $163 |
| 2020 | $90 | $153 | $45–$1,000 | $114 |
| 2021 | $0 | $261 | $100–$1,355 | $132 |
| 2022 | $0 | $242 | $87–$1,273 | $149 |
| 2023 | $0 | $322 | $97–$1,266 | $160 |
| 2024 | $0 | $247 | $70–$1,053 | $164 |
| 2025 | $0 | $360 | $91–$1,472 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 16 billing codesPaid by Medicare
$202,824
Medicare patients
1,326
Services billed
1,652
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Ischemic heart disease | 39% | |
| Chronic kidney disease | 29% | |
| Diabetes | 26% | |
| Atrial fibrillation | 26% | |
| Osteoporosis | 26% | |
| Heart failure | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Vascular Neurology in California
Gregory Albers
Vascular Neurology · Stanford, CA
Chitra Venkatasubramanian
Vascular Neurology · Stanford, CA
Shuichi Suzuki
Vascular Neurology · Arcadia, CA
Royya Modir
Vascular Neurology · San Diego, CA
Maarten Lansberg
Vascular Neurology · Stanford, CA
Muhammad Taqi
Vascular Neurology · Palm Springs, CA
Related records
Vascular Neurology in California
Practitioners in the same specialty and state, ranked by reported value.
All Vascular Neurology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.